Millennium kept at neutral by Merrill

Merrill Lynch analyst Tom McGahren maintained Millennium Pharmaceuticals, Inc. at neutral on news that the company filed a supplemental New Drug Application for Velcade in the treatment of relapsed or refractory mantle cell lymphoma. The filing was expected as the company attempts a label expansion for the product, according to the analyst. Shares of the Cambridge, Mass.-based pharmaceutical company were up 13 cents, or 1.42%, at $9.31 on volume of 8,942,793 shares versus the three-month running average of 4,297,000 shares. (Nasdaq: MLNM)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.